查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1945801

肝素诱发血小板减少性疾病市场－全球产业规模、份额、趋势、机会及预测（依治疗药物、通路、地区及竞争格局划分，2021-2031年）

Heparin-Induced Thrombocytopenia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Drug, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球肝素诱发血小板减少性疾病(HIT) 市场预计将从 2025 年的 98.7 亿美元成长到 2031 年的 133.6 亿美元，复合年增长率为 5.18%。

肝素诱发的血小板减少性疾病(HIT) 是严重的抗体介导的肝素暴露反应，其特征是血小板计数迅速下降和矛盾的血栓形成倾向。市场成长的主要驱动因素是需要抗凝血治疗的复杂心血管和整形外科手术日益增多，以及临床治疗偏好转向非肝素疗法。国际血栓与止血学会 (ISTH) 的一份报告也印证了这种不断变化的治疗标准。报告指出，到 2024 年，74.5% 的受访专家支持使用Rivaroxaban伐沙班治疗 HIT，即使在血小板恢復之前，这将推动直接口服抗凝血剂 (DOAC) 的应用。

市场概览
预测期 2027-2031
市场规模：2025年 98.7亿美元
市场规模：2031年 133.6亿美元
复合年增长率：2026-2031年 5.18%
成长最快的细分市场 阿加曲班
最大的市场 北美洲

然而，该市场在诊断准确性方面面临许多障碍。广泛使用的免疫检测方法经常出现假阳性结果，这不仅使临床决策复杂化，还常常导致不必要的昂贵替代疗法的使用。这种诊断不确定性降低了患者照护效率，并给医疗保健系统带来了沉重的经济负担，从而限制了市场在成本敏感地区的扩张。

市场驱动因素

全球外科手术量的不断增长是市场发展的根本驱动力，因为肝素仍然是心肺体外迴圈和大型整形外科手术的标准抗凝血剂。随着全球人口老化，对更复杂手术的需求增加，导致未分级肝素的累积暴露增加，以及发生免疫介导不良反应的患者绝对数量增加。 2023年12月《胸腔外科年鑑》简报的数据显示，高所得国家平均每年每10万人进行123.2例心臟外科手术，凸显了肝素使用的巨大规模。这种广泛的暴露与疾病负担相关，美国血液学会估计，到2024年，肝素诱导的血栓症（HIT）将影响每年约1500名住院患者中的1人，这将持续推动对诊断和治疗解决方案的需求。

同时，非肝素抗凝血药物的日益普及正在改变市场格局。随着临床医生优先选择安全性更高的药物用于高风险患者，医疗专业人员正逐步转向使用直接凝血酶抑制剂进行易感人群的根治性治疗和预防，从而减少对传统肝素通讯协定的依赖。这一转变得到了可靠的临床证据支持。例如，2024年10月出版的《美国心臟学会杂誌》报道，在一项针对接受经皮皮冠状动脉介入治疗（PCI）患者的大型Meta分析中，比伐卢定将30天全因死亡率降低至2.5%，而肝素组为2.9%。诸如此类的研究结果正在加速非肝素类药物被纳入医院处方集，从而推动了替代抗凝血药物的收入成长。

市场挑战

全球肝素诱发血小板减少性疾病(HIT) 市场扩张的主要障碍在于诊断准确性方面持续存在的挑战，尤其是标准筛检试验中较高的假阳性率。儘管目前的免疫测定法灵敏度较高，但其特异性往往不足以区分致病性抗体和非致病性突变。这种诊断上的不确定性迫使医疗服务提供者在没有临床症状的情况下，也不得不预防性地停用肝素，转而使用昂贵的替代抗凝血剂。根据美国血液学会 (ASH) 2024 年的报告，临床数据显示，广泛使用的免疫检测在高达 50% 的心血管手术患者中出现假阳性结果，导致严重的诊断混乱。

这种不确定性导致医疗成本上涨和资源配置效率低下，直接影响市场成长。使用昂贵的非肝素疗法治疗假阳性病例会对医院预算造成沉重的经济负担，尤其是在对成本敏感的地区。因此，医疗机构管理者在采购高成本的替代疗法时往往会更加谨慎，这限制了销售量。由于缺乏快速且准确的诊断确认而导致的这种财务犹豫，阻碍了先进治疗方法的广泛商业性应用，并限制了整体市场收入潜力。

市场趋势

在开发平臺中，一项重要的进展是新型12-脂氧合酶（12-LOX）抑制剂的研发。这类抑制剂针对上游酶促通路，在不损害止血功能的前提下抑制血小板活化。这种作用机制代表着对传统凝血酶抑制策略的策略性转变，旨在最大程度地降低复杂病例的出血风险。例如，2024年8月，Veralox Therapeutics公司宣布，其主要候选药物VLX-1005获得了欧洲药品管理局（EMA）授予的孤儿药资格认定，用于治疗血小板活化因子4（PAF4）相关疾病。这项监管核准表明，业界正日益关注开发具有缓解疾病特性的First-in-Class小分子药物，这些药物比目前用于高风险患者群体的抗凝血剂更安全。

同时，市场正朝着快速、自动化的诊断测试方向发展，特别是化学冷光免疫检测，以克服人工检测的限制。这些系统能够在重症监护环境中快速排除诊断，从而解决假阳性结果带来的效率低下问题。 2024年6月，国际血栓与止血学会报告了一种新的化学冷光免疫检测，该方法在疑似患者中展现出77.4%的特异性，优于特异性在62.4%至74.2%之间的同类抗体检测法。这项进步使临床医生能够透过快速排除疾病并避免不必要的昂贵治疗，从而优化抗凝血治疗的合理应用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球肝素诱发血小板减少性疾病市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依治疗类型（阿加曲班、来匹卢定、达那帕罗钠、其他）
    • 按分销管道（医院/诊所、门诊护理中心、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美肝素诱发血小板减少性疾病市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲肝素诱发血小板减少性疾病市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区肝素诱发血小板减少性疾病市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲肝素诱发血小板减少性疾病市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

10. 南美肝素诱发血小板减少性疾病市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球肝素诱发血小板减少性疾病市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Mitsubishi Tanabe Pharma
  • Auromedics Pharma Llc
  • Fresenius Kabi USA
  • Pfizer Inc
  • DAIICHI SANKYO COMPANY, LIMITED
  • Caplin Steriles Ltd
  • Hikma Pharmaceuticals PLC
  • NOVARTIS AG
  • Endo International plc
  • Gland Pharma Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17290

The Global Heparin-Induced Thrombocytopenia Market is projected to expand from USD 9.87 Billion in 2025 to USD 13.36 Billion by 2031, registering a compound annual growth rate of 5.18%. Heparin-Induced Thrombocytopenia (HIT) is defined as a serious, antibody-mediated reaction to heparin exposure, marked by a rapid decrease in platelet count and a contradictory prothrombotic condition. Market growth is primarily underpinned by the increasing frequency of complex cardiovascular and orthopedic surgeries requiring anticoagulation, alongside a shift in clinical preference toward non-heparin therapies. This evolution in therapeutic standards is highlighted by the International Society on Thrombosis and Haemostasis, which reported in 2024 that 74.5% of surveyed experts supported using rivaroxaban for HIT management even before platelet recovery, a factor that fuels the adoption of direct oral anticoagulants.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 9.87 Billion
Market Size 2031USD 13.36 Billion
CAGR 2026-20315.18%
Fastest Growing SegmentArgatroban
Largest MarketNorth America

Nevertheless, the market encounters substantial obstacles related to diagnostic precision. The frequent occurrence of false-positive results in widely utilized immunological assays complicates clinical judgment and often results in the unnecessary application of expensive alternative treatments. This diagnostic uncertainty creates inefficiencies in patient care and places significant financial strain on healthcare systems, thereby limiting broader market expansion in regions that are sensitive to costs.

Market Driver

The rising global volume of surgical procedures serves as a fundamental catalyst for the market, given that heparin remains the standard anticoagulant for cardiopulmonary bypass and major orthopedic interventions. As the global population ages and requires more frequent complex surgeries, the cumulative exposure to unfractionated heparin increases, leading to a rise in the absolute number of patients developing immune-mediated adverse reactions. Data from the Annals of Thoracic Surgery Short Reports in December 2023 indicates that high-income nations maintained an average total cardiac surgical volume of 123.2 procedures per 100,000 people annually, highlighting the massive scale of heparin utilization. This widespread exposure correlates with disease burden, as the American Society of Hematology estimated in 2024 that HIT affects approximately 1 in 1,500 hospitalizations annually, driving sustained demand for diagnostic and therapeutic solutions.

Concurrently, the increasing adoption of non-heparin anticoagulant therapies is reshaping the market landscape as clinicians prioritize agents with superior safety profiles for high-risk patients. Medical professionals are shifting toward direct thrombin inhibitors for both confirmed treatment and prevention in susceptible cohorts, reducing reliance on traditional heparin protocols. This transition is supported by robust clinical evidence; for instance, the Journal of the American College of Cardiology reported in October 2024 that a large-scale meta-analysis of patients undergoing primary percutaneous coronary intervention showed bivalirudin reduced 30-day all-cause mortality to 2.5%, compared to 2.9% for heparin. Such findings accelerate the integration of non-heparin pharmacotherapies into hospital formularies and drive revenue growth for alternative anticoagulants.

Market Challenge

The primary impediment hindering the expansion of the Global Heparin-Induced Thrombocytopenia Market is the persistent challenge regarding diagnostic accuracy, particularly the high rate of false-positive results associated with standard screening tests. Although current immunological assays are sensitive, they frequently lack the necessary specificity to differentiate between pathogenic antibodies and non-pathogenic variations. This diagnostic ambiguity compels healthcare providers to discontinue heparin and initiate expensive alternative anticoagulants as a precaution, even when the clinical condition is not present. According to the American Society of Hematology in 2024, clinical data indicated that widely utilized immunoassays yield false-positive results in up to 50 percent of cardiac surgery patients, leading to significant diagnostic confusion.

This uncertainty directly impacts market growth by inflating healthcare costs and creating inefficiencies in resource allocation. The financial burden incurred from treating false-positive cases with premium non-heparin therapies strains hospital budgets, particularly in cost-sensitive regions. Consequently, healthcare administrators often exercise greater fiscal caution in procuring high-cost alternative drugs, which limits sales volumes. This economic hesitation, driven by the inability to rapidly and accurately confirm the diagnosis, restricts the broader commercial adoption of advanced therapeutics and suppresses overall market revenue potential.

Market Trends

A significant trend in the development pipeline is the advancement of novel 12-lipoxygenase (12-LOX) inhibitors, which target upstream enzymatic pathways to reduce platelet activation without compromising hemostasis. This mechanism represents a strategic departure from traditional thrombin inhibition, aiming to minimize bleeding risks in complex cases. For example, Veralox Therapeutics announced in August 2024 that the European Medicines Agency granted Orphan Drug Designation to their lead candidate, VLX-1005, for treating platelet-activating anti-Platelet Factor 4 disorders. This regulatory endorsement highlights the growing industry commitment to developing first-in-class small molecule drugs that provide safer, disease-modifying alternatives to current anticoagulants for high-risk patient populations.

Simultaneously, the market is observing a transition toward rapid automated diagnostic assays, particularly chemiluminescent immunoassays, to overcome the limitations of manual testing. These systems facilitate quicker exclusion of diagnoses in critical care settings, addressing inefficiencies caused by false-positive results. In June 2024, the International Society on Thrombosis and Haemostasis highlighted a new chemiluminescent immunoassay that demonstrated a specificity of 77.4% in suspected patients, outperforming comparative antibody assays which ranged between 62.4% and 74.2%. This advancement enables clinicians to optimize anticoagulant stewardship by rapidly ruling out the condition, preventing the unnecessary utilization of expensive therapies.

Key Market Players

  • Mitsubishi Tanabe Pharma
  • Auromedics Pharma Llc
  • Fresenius Kabi USA
  • Pfizer Inc
  • DAIICHI SANKYO COMPANY, LIMITED
  • Caplin Steriles Ltd
  • Hikma Pharmaceuticals PLC
  • NOVARTIS AG
  • Endo International plc
  • Gland Pharma Ltd

Report Scope

In this report, the Global Heparin-Induced Thrombocytopenia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Heparin-Induced Thrombocytopenia Market, By Treatment Drug

  • Argatroban
  • Lepirudin
  • Danaparoid
  • Others

Heparin-Induced Thrombocytopenia Market, By Distribution Channel

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Heparin-Induced Thrombocytopenia Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Heparin-Induced Thrombocytopenia Market.

Available Customizations:

Global Heparin-Induced Thrombocytopenia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Heparin-Induced Thrombocytopenia Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Drug (Argatroban, Lepirudin, Danaparoid, Others)
    • 5.2.2. By Distribution Channel (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Heparin-Induced Thrombocytopenia Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Drug
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Heparin-Induced Thrombocytopenia Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Drug
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Heparin-Induced Thrombocytopenia Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Drug
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Heparin-Induced Thrombocytopenia Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Drug
        • 6.3.3.2.2. By Distribution Channel

7. Europe Heparin-Induced Thrombocytopenia Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Drug
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Heparin-Induced Thrombocytopenia Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Drug
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Heparin-Induced Thrombocytopenia Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Drug
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Heparin-Induced Thrombocytopenia Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Drug
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Heparin-Induced Thrombocytopenia Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Drug
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Heparin-Induced Thrombocytopenia Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Drug
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Heparin-Induced Thrombocytopenia Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Drug
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Heparin-Induced Thrombocytopenia Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Drug
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Heparin-Induced Thrombocytopenia Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Drug
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Heparin-Induced Thrombocytopenia Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Drug
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Heparin-Induced Thrombocytopenia Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Drug
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Heparin-Induced Thrombocytopenia Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Drug
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Heparin-Induced Thrombocytopenia Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Drug
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Heparin-Induced Thrombocytopenia Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Drug
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Heparin-Induced Thrombocytopenia Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Drug
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Heparin-Induced Thrombocytopenia Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Drug
        • 9.3.3.2.2. By Distribution Channel

10. South America Heparin-Induced Thrombocytopenia Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Drug
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Heparin-Induced Thrombocytopenia Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Drug
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Heparin-Induced Thrombocytopenia Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Drug
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Heparin-Induced Thrombocytopenia Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Drug
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Heparin-Induced Thrombocytopenia Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Mitsubishi Tanabe Pharma
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Auromedics Pharma Llc
  • 15.3. Fresenius Kabi USA
  • 15.4. Pfizer Inc
  • 15.5. DAIICHI SANKYO COMPANY, LIMITED
  • 15.6. Caplin Steriles Ltd
  • 15.7. Hikma Pharmaceuticals PLC
  • 15.8. NOVARTIS AG
  • 15.9. Endo International plc
  • 15.10. Gland Pharma Ltd

16. Strategic Recommendations

17. About Us & Disclaimer